Myelodysplastic Syndromes
"Myelodysplastic Syndromes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.
| Descriptor ID |
D009190
|
| MeSH Number(s) |
C15.378.190.625
|
| Concept/Terms |
Myelodysplastic Syndromes- Myelodysplastic Syndromes
- Myelodysplastic Syndrome
- Syndrome, Myelodysplastic
- Syndromes, Myelodysplastic
- Dysmyelopoietic Syndromes
- Dysmyelopoietic Syndrome
- Syndrome, Dysmyelopoietic
- Syndromes, Dysmyelopoietic
Hematopoetic Myelodysplasia- Hematopoetic Myelodysplasia
- Hematopoetic Myelodysplasias
- Myelodysplasia, Hematopoetic
- Myelodysplasias, Hematopoetic
|
Below are MeSH descriptors whose meaning is more general than "Myelodysplastic Syndromes".
Below are MeSH descriptors whose meaning is more specific than "Myelodysplastic Syndromes".
This graph shows the total number of publications written about "Myelodysplastic Syndromes" by people in this website by year, and whether "Myelodysplastic Syndromes" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 3 | 0 | 3 |
| 1997 | 3 | 0 | 3 |
| 1998 | 4 | 0 | 4 |
| 2000 | 2 | 0 | 2 |
| 2001 | 1 | 1 | 2 |
| 2002 | 4 | 2 | 6 |
| 2003 | 1 | 0 | 1 |
| 2006 | 1 | 1 | 2 |
| 2007 | 2 | 0 | 2 |
| 2008 | 3 | 1 | 4 |
| 2009 | 1 | 1 | 2 |
| 2010 | 3 | 0 | 3 |
| 2011 | 2 | 0 | 2 |
| 2012 | 2 | 0 | 2 |
| 2013 | 1 | 0 | 1 |
| 2014 | 5 | 1 | 6 |
| 2015 | 1 | 0 | 1 |
| 2016 | 2 | 2 | 4 |
| 2017 | 2 | 1 | 3 |
| 2018 | 2 | 0 | 2 |
| 2019 | 2 | 0 | 2 |
| 2020 | 5 | 0 | 5 |
| 2021 | 7 | 0 | 7 |
| 2022 | 4 | 0 | 4 |
| 2023 | 2 | 1 | 3 |
| 2024 | 5 | 2 | 7 |
To return to the timeline,
click here.
Below are the most recent publications written about "Myelodysplastic Syndromes" by people in Profiles.
-
[VEXAS-like auto inflammatory syndrome: 2?cases]. Rev Med Interne. 2025 Mar; 46(3):139-145.
-
Superior Survival After Unrelated Allogeneic Stem Cell Transplantation With Low-Dose ATG Compared to Low-Dose TBI in Myeloablative Fludarabine/Busulfan-Based Regimen for MDS on Behalf of the Adult MDS Working Group of the JSTCT. Transplant Cell Ther. 2025 Jan; 31(1):18.e1-18.e12.
-
Update on Recommendations for Surveillance for Children with Predisposition to Hematopoietic Malignancy. Clin Cancer Res. 2024 Oct 01; 30(19):4286-4295.
-
Characteristics and outcomes of children, adolescent, and young adult patients with myelodysplastic neoplasms: A single-center retrospective analysis. Leuk Res. 2024 Sep; 144:107563.
-
Impact of Early Cytomegalovirus Reactivation After Allogeneic Hematopoietic Stem Cell Transplantation on Relapse in Patients With Myelodysplastic Syndrome: A Nationwide Retrospective Study From Adult Myelodysplastic Syndrome Working Group of the JSTCT. Transplant Cell Ther. 2024 07; 30(7):685.e1-685.e12.
-
Exploring the landscape of somatic ASXL2 mutations in myeloid neoplasms: Frequency and clinical implications. Am J Hematol. 2024 07; 99(7):1434-1436.
-
Myelodysplastic neoplasms evolving from inherited bone marrow failure syndromes / germline predisposition syndromes: Back under the microscope. Leuk Res. 2024 02; 137:107441.
-
Sequential vs myeloablative vs reduced intensity conditioning for patients with myelodysplastic syndromes with an excess of blasts at time of allogeneic haematopoietic cell transplantation: a retrospective study by the chronic malignancies working party of the EBMT. Bone Marrow Transplant. 2024 02; 59(2):224-231.
-
Prevalence and significance of DDX41 gene variants in the general population. Blood. 2023 10 05; 142(14):1185-1192.
-
Feasibility of pevonedistat combined with azacitidine, fludarabine, cytarabine in pediatric relapsed/refractory AML: Results from COG ADVL1712. Pediatr Blood Cancer. 2023 12; 70(12):e30672.